Option Care ha sido seleccionado como proveedor preferido de terapia de infusión en el hogar de inmunoglobulina para los miembros de AmeriHealth
By: Option Care
March 1, 2016
Effective March 1, 2016, Option Care Enterprises, Inc. will be a preferred provider of intravenous and subcutaneous immunoglobulin (IVIG/SCIG) drugs provided in the home* for members covered by AmeriHealth New Jersey.
As one of the nation’s largest providers of home and alternate treatment site infusion services, Option Care’s specially trained nurses and pharmacists provide high-quality, high-touch clinical support to patients treated for complex conditions, including those receiving IG. Option Care IG patients report very high levels of satisfaction — 98 percent — with Option Care’s in-home visits and ongoing support calls to help them manage their conditions.[*]Option Care Enterprises, Inc. Data on file 2016.
IG therapy is prescribed to patients with immune system-related conditions, including primary immunodeficiency disorders (the body’s immune system doesn’t function properly), autoimmune disorders (the body attacks itself) and other conditions that benefit from the treatment. IG therapy is delivered one of two ways: IVIG is infused through a vein, and SCIG is delivered into the fatty tissue just below the skin. Including IVIG and SCIG, Option Care manages more than 55,000 IG infusions each year.[*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
Home Infusion IG Therapy in Focus
En un estudio pionero reciente, los pacientes de Option Care en tratamiento con inmunoglobulina en el hogar, que reciben un nivel alto de supervisión clínica, tuvieron mejores resultados en comparación con una gran base de datos nacional de pacientes que reciben terapia de inmunoglobulina en otros entornos.
Option Care proporciona acceso a todos los productos con inmunoglobulina, y sus más de 1700 profesionales clínicos, entre ellos, enfermeros y farmacéuticos capacitados especialmente en IGIV/IGSC, brindan atención de alta calidad que comprende planes personalizados de atención, monitoreo clínico de cada infusión y educación integral del paciente y del cuidador.
*Los miembros pueden seguir recibiendo inmunoglobulina por vía subcutánea/intravenosa de los proveedores de infusión en el hogar que pertenecen actualmente a un hospital o sistema de salud y participan en la red de proveedores de AmeriHealth en New Jersey.
You might also be interested in:
Home and Alternate Site Infusion Therapy Providers BioScrip and Option Care to Merge
Creates a Leading Independent Provider of Home and Alternate Site Infusion Services with Deep Clinical Expertise and Broad Therapy Portfolio Enhanced Scale and Improved Financial Profile Expected to Enable Growth in Attractive and Growing Segment of U.S. Healthcare Market BioScrip to Issue New Shares to Option Care’s Shareholder, Which Will Own Approximately 80% of Combined […]
Presentamos Option Care, la evolución del nombre y marca de Walgreens Infusion Services
DEERFIELD, Ill. — Option Care, a new, independent infusion services company previously known as Walgreens Infusion Services, today unveiled its new name and company branding. Option Care is majority owned by Madison Dearborn Partners (MDP), a leading private equity firm based in Chicago; and minority owned by Walgreen Co., a wholly owned subsidiary of Walgreens […]